Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.40 |
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.38 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27762272 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2D6CYP1A2CYP2C19PRCP | |
| Hydrochloric Acid SCHEMBL51792 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2D6CYP1A2CYP2C19PRCP | |
| Hydrochloric Acid SCHEMBL1223341 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2D6CYP1A2CYP2C19PRCP | |
| Hydrochloric Acid SCHEMBL17064017 | 0.98 | CYP3A4 (0.43) | CYP3A4CYP2D6CYP1A2CYP2C19PRCP | |
| SCHEMBL51793 | 0.98 | — | — | |
| SCHEMBL708271 | 0.98 | — | — | |
| SCHEMBL118100 | 0.98 | — | — | |
| Ammonia Solution, Strong SCHEMBL16464378 | 0.96 | CYP3A4 (0.44) | CYP3A4CYP2D6CYP1A2CYP2C19PRCP | |
| Water SCHEMBL16400402 | 0.96 | CYP3A4 (0.44) | CYP3A4CYP2D6CYP1A2CYP2C19PRCP | |
| SCHEMBL2237837 | 0.96 | CYP3A4 (0.44) | CYP3A4CYP2D6CYP1A2CYP2C19PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 676 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339396-A1 | NOVEL MODULATORS OF THE MELATONIN RECEPTORS AS WELL AS METHOD OF MANUFACTURE AND USES THEREOF | COSMAS THERAPEUTICS DEVELOPMENT INC. (CA) | 2025-11-06 | — | — | US | claimed |
| CN-119874660-A | Amino acid derivative-rhodamine B conjugate, preparation method thereof and application thereof as fluorescent tracer | 内蒙古农业大学 | 2025-04-25 | — | — | CN | claimed |
| CN-113527399-B | Ginsenoside CK derivative and application thereof in preparation of antitumor drugs | 陕西巨子生物技术有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-113527399-A | Ginsenoside CK derivative and application thereof in preparation of antitumor drugs | 陕西巨子生物技术有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-113087699-A | Peptide-like compound and preparation method and application thereof | 盐城工业职业技术学院 | 2021-07-09 | — | — | CN | claimed |
| CN-106674230-B | The synthetic method of pro-his cyclic dipeptide | 陕西慧康生物科技有限责任公司 | 2019-07-02 | — | — | CN | claimed |
| CN-107641092-A | A kind of synthetic method of L prolineamides | 广东肇庆星湖生物科技股份有限公司 | 2018-01-30 | — | — | CN | claimed |
| CN-106977441-A | A kind of preparation method of R diphenylprolinols | 蚌埠中实化学技术有限公司 | 2017-07-25 | — | — | CN | claimed |
| CN-106674230-A | Synthesis method of histidine and proline cyclodipeptide | 陕西慧康生物科技有限责任公司 | 2017-05-17 | — | — | CN | claimed |
| CN-105343097-A | Composition containing caffeine and application and manufacturing method of composition containing caffeine | TIANJIN JIANLAIDE TECHNOLOGY CO LTD | 2016-02-24 | — | — | CN | claimed |
| CN-104926578-A | Preparation method for fatty acyl amide | LANZHOU CHEM PHYS INST | 2015-09-23 | — | — | CN | claimed |
| CN-104447759-A | Production method for cyclic dipeptide | UNIV JILIN AGRICULTURAL | 2015-03-25 | — | — | CN | claimed |
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-06-10 | — | — | US | claimed |
| EP-3672582-B1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS SINAI MEDICAL CENTER (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-3801553-B1 | PRODRUGS OF FULVESTRANT | KASHIV BIOSCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12582742-B2 | Packaging solutions | BAUSCH + LOMB IRELAND LIMITED (IE) | 2026-03-24 | — | — | US | disclosed |
| EP-0155809-A2 | Renin inhibitors containing statine or derivatives thereof | PFIZER INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| US-4033974-A | Pyridylmethyl esters of N-(phenoxyalkanoyl)peptide derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-07-05 | — | — | US | disclosed |
| US-3956484-A | Pyridylmethyl esters of N-(phenoxyalkanoyl)peptide derivatives for therepeutic use | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
| US-3948971-A | N-protected-α-amino acid compounds | MERCK & CO., INC. (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339396-A1 | NOVEL MODULATORS OF THE MELATONIN RECEPTORS AS WELL AS METHOD OF MANUFACTURE AND USES THEREOF | MTNR1A, MTNR1B, PER2 | DPP4 3402/4885CHRNB4 939/4885CHRNA3 451/4885 |
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | DCK, DHPS, DHX15 | DPP4 830/4885CHRNB4 4877/4885CHRNA3 4878/4885 |
| US-12582742-B2 | Packaging solutions | CD44, DSG1, HPSE | DPP4 1760/4885CHRNB4 4098/4885CHRNA3 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.